Skip to main content
S

SKYBIOTECH HEALTHCARE LIMITED — Investor Relations & Filings

Ticker · 512036 ISIN · INE393H01016 BSE.NS Manufacturing
Open in API
Filings indexed 272 across all filing types
Latest filing 2026-05-30 Interim / Quarterly Rep…
Country IN India
Listing BSE.NS 512036

About SKYBIOTECH HEALTHCARE LIMITED

Skybiotech Healthcare Limited focuses on the development, manufacturing, and distribution of a wide range of healthcare products. The company specializes in various therapeutic segments, including anti-infectives, analgesics, anti-inflammatory agents, and nutritional supplements. Its product portfolio encompasses diverse dosage forms such as tablets, capsules, liquid orals, and injectables. Skybiotech Healthcare Limited emphasizes quality assurance and adherence to regulatory standards to ensure the efficacy and safety of its formulations. The organization serves a broad network of healthcare providers and institutions, aiming to improve patient outcomes through accessible medical solutions.

Recent filings

Filing Released Lang Actions
Submission of Financial Results for the Quarter and Year ended on 31st March 2026
Interim / Quarterly Report Classification · 84% confidence The document is a regulatory submission under SEBI Listing Regulations containing the Board’s approval of audited financial results for the quarter and year ended March 31, 2026, the Independent Auditor’s Report thereon, and the detailed standalone audited financial statements (profit and loss, balance sheet, cash flows, notes). It is not a full annual report (10-K) or mere earnings highlights (ER), nor just an audit certificate (AR) or report publication notice (RPA). It is a comprehensive financial report for a period shorter than (and including) the full fiscal year, filed in lieu of the quarterly/interim audited results. Therefore, it best fits the “Interim / Quarterly Report” category (IR). FY 2026
2026-05-30 English
Submission of Outcome of board meeting and Financial Results for the quarter and year ended on 31st March 2026
Interim / Quarterly Report Classification · 97% confidence The document is a formal Listing Obligations & Disclosure Requirements (LODR) filing to BSE by Skybiotech Healthcare Limited dated 30 May 2026. It contains the Board’s approval of the audited financial results (standalone and consolidated) for the quarter and year ended 31 March 2026, the Independent Auditor’s Report, and the full set of financial statements for the quarter and year. This is not a brief earnings highlight (ER) or an annual report (10-K), but a full interim/quarterly financial report with substantive financial data. Under FinancialReports taxonomy, this corresponds to an Interim / Quarterly Report (IR). FY 2026
2026-05-30 English
Skybiotech Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve Approval of Audited Results ....
Regulatory Filings Classification · 85% confidence The document is an intimation to the stock exchange under SEBI LODR Regulation 29(1)(a) announcing the scheduling of a Board of Directors meeting to consider audited financial results. It contains no financial data itself, no proxy materials, and no actual report – it is a regulatory notice. This does not match specific categories like Annual Report, Earnings Release, Management Change, or Board changes, so it falls under general regulatory announcements (RNS).
2026-05-26 English
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details ....
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the listing department of BSE Limited, confirming that Skybiotech Healthcare Limited does not fall under the category of 'Large Entities' as per specific SEBI circulars related to fund raising by issuance of debt securities. It is a compliance confirmation rather than a financial report or detailed disclosure. The document is short (1577 characters) and serves as a regulatory compliance confirmation. It does not contain financial statements, audit information, or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and compliance confirmations.
2026-04-30 English
Certificate under Reg. 74(5) of SEBI (DP) Regulation, 2018 received from RTA
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming details about dematerialization of shares for the quarter ended 31st March 2026. It is addressed to the stock exchange listing department and includes a certification from the Registrar and Share Transfer Agent. The document is short (2529 characters) and primarily serves as a regulatory compliance certificate rather than a financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for compliance certificates and miscellaneous regulatory documents that do not fit other specific categories.
2026-04-09 English
Intimation of Trading window closure to consider and approve Audited Financials for the Quarter and year ended on 31st March 2026
Regulatory Filings Classification · 95% confidence The document is a short notice from Skybiotech Healthcare Limited to the stock exchange regarding the closure of the trading window in compliance with SEBI regulations ahead of the announcement of audited financial results for the quarter and year ended March 31, 2026. It does not contain any financial data or results itself, nor does it include detailed report content. It is an announcement about the trading window closure and the upcoming board meeting date to approve financial results, which will be communicated later. The document length is only 1593 characters, indicating it is a brief regulatory announcement rather than a full report. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance notification rather than a financial report or earnings release.
2026-03-30 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.